首页> 外文OA文献 >Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure
【2h】

Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure

机译:内脏利什曼病患者与亚临床感染者和药物治愈者的免疫力不同:对药物治愈机制的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Significant levels of IgG3 and IgG4 and high levels of IgG1 leishmania-specific antibody differentiated the immune states in 10 patients with visceral leishmaniasis from those of virtually all 20 drug-cured and 18 subclinically infected subjects, whereas the level of IgG2 antibody was nondiscriminating. The most extreme "subclinically infected" outlier subsequently developed disease. Overall, the immune states in subclinically infected and drug-cured persons were mutually indistinguishable but were readily distinguished from those of patients. These findings may have implications for the immunologic mechanism underlying drug cure in visceral leishmaniasis
机译:IgG3和IgG4的显着水平以及IgG1利什曼原虫特异性抗体的高水平将10例内脏利什曼病患者的免疫状态与几乎所有20例药物治愈的患者和18名亚临床感染的受试者的免疫状态区分开,而IgG2抗体的水平却没有区别。最极端的“亚临床感染”异常值随后发展为疾病。总体而言,亚临床感染者和药物治愈者的免疫状态是相互无法区分的,但很容易与患者区分开。这些发现可能对内脏利什曼病药物治疗的免疫机制有重要意义

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号